Bionano Genomics' subsidiary announced that MolDX has issued a proposed Local Coverage Determination (LCD) for genome-wide molecular methodologies, including Bionano's optical genome mapping (OGM), for detecting genetic alterations in hematologic neoplasms. This proposed LCD, if finalized, would establish Medicare coverage criteria for these advanced diagnostic tests, potentially expanding market access for Bionano's OGM-Dx HemeOne test.
Bionano Genomics' subsidiary, Bionano Laboratories, announced that MolDX, a Medicare program, has issued a proposed Local Coverage Determination (LCD) for genome-wide molecular methodologies, including optical genome mapping (OGM), for detecting genetic alterations in blood cancers. This is a significant development because it outlines potential Medicare coverage for these advanced diagnostic tests, which could substantially increase their adoption and reimbursement. For Bionano, whose OGM-Dx HemeOne test is designed for this application, this represents a major opportunity to expand its market reach and revenue. While the LCD is still in a public comment period and not yet finalized, its proposal signals a positive shift towards broader acceptance and reimbursement for OGM technology in the diagnostic landscape, offering a long-term tailwind for BNGO, though short-term market reaction will depend on investor sentiment regarding the likelihood of final approval and its timing.